Screening for cervical cancer: Choices & dilemmas

被引：42

作者：

Rajaram, Shalini ^{[1
,3
]}

Gupta, Bindiya ^{[2
]}

机构：

[1] All India Inst Med Sci, Dept Obstet & Gynecol, Rishikesh, Uttarakhand, India

[2] Univ Coll Med Sci & Guru Teg Bahadur Hosp, Delhi, India

[3] AIIMS Rishikesh, Dept Obstet & Gynecol, Veerbhadra Rd, Rishikesh 249203, Uttaranchal, India

来源：

INDIAN JOURNAL OF MEDICAL RESEARCH | 2021年 / 154卷 / 02期

关键词：

Biomarker; cervical cancer screening; cervical cytology; DNA methylation; HPV DNA testing; p16/Ki 67 dual staining; VIA; HUMAN-PAPILLOMAVIRUS DNA; HPV-POSITIVE WOMEN; LIQUID-BASED CYTOLOGY; EXTENDED FOLLOW-UP; CLINICAL-PERFORMANCE; VISUAL INSPECTION; ACETIC-ACID; INTRAEPITHELIAL NEOPLASIA; BASE-LINE; RISK;

D O I：

10.4103/ijmr.IJMR_857_20

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cervical cancer is the fourth most common cancer in women in the world. To eliminate cervical cancer by 2030, the World Health Organization has given the target of 70 per cent coverage of twice lifetime screening. A multitude of screening methods are available, including cytology, human papillomavirus (HPV) DNA testing and visual inspection tests. Precision tests, including molecular and protein biomarkers such as DNA methylation, p16 immunostaining, and HPV mRNA testing help to enhance specificity of the screening. Worldwide HPV DNA testing with or without cytology is used as a screening method of choice, while in resource-poor settings, visual inspection tests are recommended. The major hurdle is a uniform and systematic implementation with a recall method in the population. Besides, controversies still exist regarding strategies to manage HPV-positive women and developing guidelines to screen the vaccinated population.

引用

页码：210 / 220

页数：11

共 79 条

[11] Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries [J].

Canfell, Karen ;

Kim, Jane J. ;

Brisson, Marc ;

Keane, Adam ;

Simms, Kate T. ;

Caruana, Michael ;

Burger, Emily A. ;

Martin, Dave ;

Nguyen, Diep T. N. ;

Benard, Elodie ;

Sy, Stephen ;

Regan, Catherine ;

Drolet, Melanie ;

Gingras, Guillaume ;

Laprise, Jean-Francois ;

Torode, Julie ;

Smith, Megan A. ;

Fidarova, Elena ;

Trapani, Dario ;

Bray, Freddie ;

Ilbawi, Andre ;

Broutet, Nathalie ;

Hutubessy, Raymond .

LANCET, 2020, 395 (10224) :591-603

[12] Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia [J].

Canfell, Karen ;

Saville, Marion ;

Caruana, Michael ;

Gebski, Val ;

Darlington-Brown, Jessica ;

Brotherton, Julia ;

Heley, Stella ;

Castle, Philip E. .

BMJ OPEN, 2018, 8 (01)

[13] Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial [J].

Carozzi, Francesca ;

Gillio-Tos, Anna ;

Confortini, Massimo ;

Del Mistro, Annarosa ;

Sani, Cristina ;

De Marco, Laura ;

Girlando, Salvatore ;

Rosso, Stefano ;

Naldoni, Carlo ;

Dalla Palma, Paolo ;

Zorzi, Manuel ;

Giorgi-Rossi, Paolo ;

Segnan, Nereo ;

Cuzick, Jack ;

Ronco, Guglielmo .

LANCET ONCOLOGY, 2013, 14 (02) :168-176

[14] Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial [J].

Cook, Darrel A. ;

Smith, Laurie W. ;

Law, Jennifer H. ;

Mei, Wendy ;

Gondara, Lovedeep ;

van Niekerk, Dirk J. ;

Ceballos, Kathy M. ;

Jang, Dan ;

Chernesky, Max ;

Franco, Eduardo L. ;

Ogilvie, Gina S. ;

Coldman, Andrew J. ;

Krajden, Mel .

JOURNAL OF CLINICAL VIROLOGY, 2018, 108 :32-37

[15] Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial [J].

Cook, Darrel A. ;

Smith, Laurie W. ;

Law, Jennifer ;

Mei, Wendy ;

van Niekerk, Dirk J. ;

Ceballos, Kathy ;

Gondara, Lovedeep ;

Franco, Eduardo L. ;

Coldman, Andrew J. ;

Ogilvie, Gina S. ;

Jang, Dan ;

Chernesky, Max ;

Krajden, Mel .

JOURNAL OF CLINICAL VIROLOGY, 2017, 87 :23-29

[16] Clinical Performance of Roche Cobas 4800 HPV Test [J].

Cui, Miao ;

Chan, Nicholas ;

Liu, Momo ;

Thai, Khanh ;

Malaczynska, Joanna ;

Singh, Ila ;

Zhang, David ;

Ye, Fei .

JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (06) :2210-2211

[17] Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs [J].

Cuschieri, Kate ;

Ronco, Guglielmo ;

Lorincz, Attila ;

Smith, Laurie ;

Ogilvie, Gina ;

Mirabello, Lisa ;

Carozzi, Francesca ;

Cubie, Heather ;

Wentzensen, Nicolas ;

Snijders, Peter ;

Arbyn, Marc ;

Monsonego, Joe ;

Franceschi, Silvia .

INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (04) :735-745

[18] Clinical, colposcopic and pathological characteristics of cervical and vaginal high-grade lesions negative for HPV by Hybrid Capture 2 [J].

del Pino, Marta ;

Rodriguez-Carunchio, Leonardo ;

Alonso, Immaculada ;

Torne, Aureli ;

Rodriguez, Agata ;

Fuste, Pere ;

Castillo, Paola ;

Nonell, Roser ;

Abu-Lhiga, Nadia ;

Ordi, Jaume .

GYNECOLOGIC ONCOLOGY, 2011, 122 (03) :515-520

[19]

Denny L, 2000, CANCER-AM CANCER SOC, V89, P826, DOI 10.1002/1097-0142(20000815)89:4<826::AID-CNCR15>3.0.CO

[20]

2-5

← 1 2 3 4 5 6 7 8 →